Teyssonneau, D.; Thiery-Vuillemin, A.; Dariane, C.; Barret, E.; Beauval, J.-B.; Brureau, L.; Créhange, G.; Fiard, G.; Fromont, G.; Gauthé, M.;
et al. PARP Inhibitors as Monotherapy in Daily Practice for Advanced Prostate Cancers. J. Clin. Med. 2022, 11, 1734.
https://doi.org/10.3390/jcm11061734
AMA Style
Teyssonneau D, Thiery-Vuillemin A, Dariane C, Barret E, Beauval J-B, Brureau L, Créhange G, Fiard G, Fromont G, Gauthé M,
et al. PARP Inhibitors as Monotherapy in Daily Practice for Advanced Prostate Cancers. Journal of Clinical Medicine. 2022; 11(6):1734.
https://doi.org/10.3390/jcm11061734
Chicago/Turabian Style
Teyssonneau, Diego, Antoine Thiery-Vuillemin, Charles Dariane, Eric Barret, Jean-Baptiste Beauval, Laurent Brureau, Gilles Créhange, Gaëlle Fiard, Gaëlle Fromont, Mathieu Gauthé,
and et al. 2022. "PARP Inhibitors as Monotherapy in Daily Practice for Advanced Prostate Cancers" Journal of Clinical Medicine 11, no. 6: 1734.
https://doi.org/10.3390/jcm11061734
APA Style
Teyssonneau, D., Thiery-Vuillemin, A., Dariane, C., Barret, E., Beauval, J.-B., Brureau, L., Créhange, G., Fiard, G., Fromont, G., Gauthé, M., Ruffion, A., Renard-Penna, R., Mathieu, R., Sargos, P., Rouprêt, M., Ploussard, G., Roubaud, G., & on behalf of the CC-AFU, Cancerology Committee of the Association Française d’Urologie.
(2022). PARP Inhibitors as Monotherapy in Daily Practice for Advanced Prostate Cancers. Journal of Clinical Medicine, 11(6), 1734.
https://doi.org/10.3390/jcm11061734
